Home » Topics » Gastrointestinal, BioWorld Science

Gastrointestinal, BioWorld Science
RSS

Durect eyes initiation of phase IIb trial of DUR-928 in alcoholic hepatitis

Sep. 23, 2020

Ascletis begins phase I study of ASC-41 in healthy subjects

Sep. 21, 2020

Arrowhead presents interim phase II data for ARO-AAT in AATD-associated liver disease

Sep. 17, 2020

Gannex files IND for FXR agonist ASC-42 to treat NASH

Sep. 15, 2020

89bio reports phase Ib/IIa topline data on BIO89-100 in NASH

Sep. 15, 2020

Enanta begins phase I study of EDP-297 for NASH

Sep. 14, 2020

S1PR2 identified as therapeutic target in nonalcoholic fatty liver disease

Sep. 10, 2020

Gannex and Galmed collaborate to study combination of ASC-41 and aramchol for NASH

Sep. 10, 2020

Phase III trial of odevixibat in progressive familial intrahepatic cholestasis meets endpoints

Sep. 9, 2020

SERPINB3 targeting proven useful for treating NASH

Sep. 9, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Recombinant vaccine inhibits HBV-associated HCC growth
BioWorld Science
Chronic liver disease and hepatocellular carcinoma (HCC) associated with chronic hepatitis B virus (HBV) are serious health problems in highly endemic areas....